drugset / Trial / NCT00764595
Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor
Phase 2
Completed
5 enrolled
Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan
Niigata University Medical & Dental Hospital · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying the side effects of imatinib mesylate and to see how well it works in treating patients with liver metastasis from a gastrointestinal stromal tumor.
Timeline
- Start
- 2008-10
- Primary completion
- 2016-03
- Completion
- 2016-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Imatinib | Small molecule | 400 mg | Oral |